Abstract
Bcl-2 and p53 genes are implicated in cell cycle regulation with roles on programmed cell death. Consequently, presence of Bcl-2 and nuclear accumulation of p53 were proposed to confer a growth advantage tumour cells.
We have investigated their role as prognostic factors in fresh tumour samples from a cohort of twenty patients with transitional cell carcinoma of the bladder by immunohistochemical analysis in paired specimens.
Expression of Bcl-2 was observed in 11 cases (69%) and nuclear p53 accumulation in 9 (45%). In the presence of Bcl-2 protein expression, tumours showed a slightly higher rate of recurrence (55% vs. 40%) and significantly more progression (36% vs. 0%). Recurrence and progression rates were not significantly different in tumours with and without nuclear p53 overexpression (recurrence rates 56% vs. 55% and progression rates 33% vs. 27%, respectively). Grade and stage appeared as important prognosticators since 75% of grade 3 tumours showed recurrence and 50% progressed in contrast to 44% and 13%, respectively, of grades 1 and 2 tumours. Similarly, 50% of Ta-T1 tumours recurred and 20% progressed, while these rates were 75% and 75% for T2–T3 tumours. Also, expression of Bcl-2 and nuclear accumulation of p53 correlated with grade. In grade 3 tumours, 75% showed nuclear p53 overexpression and 80% cytoplasmic Bcl-2 protein. These figures were 25% and 64% for grades 1 and 2 tumours.
In conclusion, Bcl-2 protein expression in transitional cell carcinoma appears to be associated with a poorer prognosis and together with nuclear p53 overexpression They are associated with tumour de-differentiation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Özen, H.: Bladder cancer,Curr. Opin Oncol., 8, 259 (1996).
Carson, D. A., Lois, A.: Cancer progression and p53.Lancet, 346, 1009 (1995).
Lotem, J., Sachs, L.: Regulation by bcl-2, c-myc and p53 susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation —competent and defective myeloid leukemic cells.Cell Growth Differ., 4, 41 (1993).
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., Jacko, T.: p53 is required for radiation-induced apoptosis in mouse thymocytes.Nature, 362, 847 (1993).
Mercer, W. E., Shields, M. T., Lin, D., Apella, E., Ullrich S. J.: Growth suppression induced by wild-type p53 is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression.Proc. Natl. Acad. Sci. USA, 88, 1958 (1991).
Fisher, D. E.: Apoptosis in cancer therapy crossing the threshold.Cell, 78, 539 (1994).
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A.: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.Oncogene, 9, 1799 (1994).
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., Wahl, G. M.: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.Cell, 70, 937 (1993).
Hupp, T. R., Meek, D. W., Midgeley, C. A., Lane, D. P.: Regulation of the specific DNA binding function of p53.Cell, 71, 875 (1992).
Levin, A. J., Momand, J., Finlay, C. A.: The p53 tumour suppressor gene.Nature, 351, 453 (1991).
Hockenberry, D., Nunez, G., Milliman, C., Schreiber, R. D., Korsmeyer, S. J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.Nature, 348, 334 (1990).
Hockenberry, D. M., Zutter, M., Hickey, W., Nahm M., Korsmeyer, S. J.: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death.Proc. Natl. Acad. Sci. USA, 88, 6961 (1991).
Baer, R.: Bcl-2 breathes life into embryogenesis.Am. J. Pathol., 145, 7 (1994).
Kerr, J. F. R., Winterford, C. M., Harmon, B. V.: Apoptosis, its significance in cancer and cancer therapy.Cancer, 73, 2013 (1994).
Steward, B. W.: Mechanisms of apoptosis: Integration of genetic, biochemical and cellular indicators.J. Natl. Cancer Inst., 86, 1286 (1994).
Vaux, D., Cory, S., Adams, J.: Bcl-2 gene promotes haematopoetic cell survival and cooperates with c-myc to immortalize pre-b cells.Nature, 355, 440 (1988).
Allsopp, T. E., Wyatt, S., Paterson, H. F., Davies, A. M.: The protooncogene bcl-2 can selectively rescue neurotropic factor dependent neurons from apoptosis.Cell, 73, 295 (1993).
Wang, Y., Szekely, L., Okan, J., Klein, G., Wiman, G., Wiman, K. L.: Wild type p53 triggered apoptosis is inhibited by bcl-2 in a V-myc-induced T-cell lymphoma line.Oncogene, 8, 3427 (1993).
Bilim, V., Kawasaki, T., Tomito, Y., Takahashi, K., Japan, N.: Significance of simultaneous expression of bcl-2 and p53 on transitional cell cancer (T.C.C.) for tumour malignancy.J. Urol., 155, 333-A (1996).
Glick, S. H., Howell, L. P., White, R. W. D.: Relationship of p53 and bcl-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder.J. Urol., 155, 1754 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Atuĝ, F., Türkeri, L., Özyürek, M. et al. Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder. International Urology and Nephrology 30, 455–461 (1998). https://doi.org/10.1007/BF02550226
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02550226